Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.
Urokinase-type plasminogen activator (u-PA) is a serine protease involved in cancer metastasis. Using immunohistochemical methods, we examined the relation between u-PA and long-term survival in 70 patients with Dukes' B colorectal cancer. 8-year survival was 81% in patients whose tumours demonstrated low-grade epithelial u-PA staining and 43% in those with high-grade staining (log-rank test, p = 0.01). Survival was unrelated to stromal u-PA staining. These results suggest that u-PA may be useful in the identification of patients with non-metastatic colorectal cancer at risk of tumour recurrence.
Mulcahy
H E
HE
Gastroenterology and Liver Unit, St Vincent's Hospital and University College Dublin, Ireland.
Duffy
M J
MJ
Gibbons
D
D
McCarthy
P
P
Parfrey
N A
NA
O'Donoghue
D P
DP
Sheahan
K
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D015179:Colorectal Neoplasms / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
D014408:Biomarkers, Tumor; D014568:Urokinase-Type Plasminogen Activator